BioCentury
ARTICLE | Financial News

Afferent taps crossover funds for $55M series C

July 9, 2015 12:42 AM UTC

Afferent Pharmaceuticals Inc. (Boston, Mass.) raised $55 million in a series C round led by new investor Fidelity. New investors Jennison Associates; New Leaf Venture Partners; Partner Fund Management; Redmile Group; Tekla Healthcare Investors; Tekla Life Science Investors; and an undisclosed public investment fund also participated. Afferent CEO Kathy Glaub told BioCentury the company had planned to raise about $40 million.

The company expects top-line data in September from a Phase IIb trial of AF-219 to treat chronic cough, and hopes to begin Phase III testing in early 2017. Afferent also plans to begin a Phase II trial this year of the purinergic receptor P2X ligand-gated ion channel 3 ( P2X3) receptor antagonist to treat chronic cough in idiopathic pulmonary fibrosis (IPF) patients. ...